Cargando…
Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene
Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies. However, disease progression and relapse remain a major challenge for the clinical management of paediatric angiosarcoma. Com...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997097/ https://www.ncbi.nlm.nih.gov/pubmed/36910630 http://dx.doi.org/10.3389/fonc.2023.999810 |
_version_ | 1784903189283209216 |
---|---|
author | Cervi, Catherine Sápi, Zoltán Bedics, Gábor Zajta, Erik Hegyi, Lajos Pápay, Judit Dezső, Katalin Varga, Edit Mudra, Katalin Bödör, Csaba Csóka, Monika |
author_facet | Cervi, Catherine Sápi, Zoltán Bedics, Gábor Zajta, Erik Hegyi, Lajos Pápay, Judit Dezső, Katalin Varga, Edit Mudra, Katalin Bödör, Csaba Csóka, Monika |
author_sort | Cervi, Catherine |
collection | PubMed |
description | Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies. However, disease progression and relapse remain a major challenge for the clinical management of paediatric angiosarcoma. Comprehensive genomic profiling of these rare tumours using high-throughput sequencing technologies may improve patient stratification and identify actionable biomarkers for therapeutic intervention. Here, we describe the clinical, histopathological, immunohistochemical and molecular profile of a novel and precision medicine-informed case where a KHDRBS1-NTRK3 fusion determined by next-generation sequencing-based comprehensive genomic profiling led to complete and sustained remission (clinical and radiological response) in an otherwise incurable disease. Our patient represents the first paediatric angiosarcoma harbouring a targetable NTRK3 fusion in the literature and demonstrates the first example of targeting this alteration in angiosarcoma using larotrectinib, an NTRK inhibitor. Clinical and radiological remission was achieved in under two months of therapy, and the patient is currently in complete remission, 4 month after stopping larotrectinib therapy, which was given over 17 months with only mild side effects reported. Therefore, this remarkable case exemplifies the true essence of precision-based care by incorporating conventional pathology with the why, when, and how to test for rare oncogenic drivers and agnostic biomarkers in paediatric angiosarcoma. |
format | Online Article Text |
id | pubmed-9997097 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99970972023-03-10 Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene Cervi, Catherine Sápi, Zoltán Bedics, Gábor Zajta, Erik Hegyi, Lajos Pápay, Judit Dezső, Katalin Varga, Edit Mudra, Katalin Bödör, Csaba Csóka, Monika Front Oncol Oncology Significant improvements in the survival rates of paediatric cancer have been achieved over the past decade owing to recent advances in therapeutic and diagnostic strategies. However, disease progression and relapse remain a major challenge for the clinical management of paediatric angiosarcoma. Comprehensive genomic profiling of these rare tumours using high-throughput sequencing technologies may improve patient stratification and identify actionable biomarkers for therapeutic intervention. Here, we describe the clinical, histopathological, immunohistochemical and molecular profile of a novel and precision medicine-informed case where a KHDRBS1-NTRK3 fusion determined by next-generation sequencing-based comprehensive genomic profiling led to complete and sustained remission (clinical and radiological response) in an otherwise incurable disease. Our patient represents the first paediatric angiosarcoma harbouring a targetable NTRK3 fusion in the literature and demonstrates the first example of targeting this alteration in angiosarcoma using larotrectinib, an NTRK inhibitor. Clinical and radiological remission was achieved in under two months of therapy, and the patient is currently in complete remission, 4 month after stopping larotrectinib therapy, which was given over 17 months with only mild side effects reported. Therefore, this remarkable case exemplifies the true essence of precision-based care by incorporating conventional pathology with the why, when, and how to test for rare oncogenic drivers and agnostic biomarkers in paediatric angiosarcoma. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9997097/ /pubmed/36910630 http://dx.doi.org/10.3389/fonc.2023.999810 Text en Copyright © 2023 Cervi, Sápi, Bedics, Zajta, Hegyi, Pápay, Dezső, Varga, Mudra, Bödör and Csóka https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cervi, Catherine Sápi, Zoltán Bedics, Gábor Zajta, Erik Hegyi, Lajos Pápay, Judit Dezső, Katalin Varga, Edit Mudra, Katalin Bödör, Csaba Csóka, Monika Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title | Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title_full | Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title_fullStr | Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title_full_unstemmed | Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title_short | Case report: Complete and durable response to larotrectinib (TRK inhibitor) in an infant diagnosed with angiosarcoma harbouring a KHDRBS1-NTRK3 fusion gene |
title_sort | case report: complete and durable response to larotrectinib (trk inhibitor) in an infant diagnosed with angiosarcoma harbouring a khdrbs1-ntrk3 fusion gene |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9997097/ https://www.ncbi.nlm.nih.gov/pubmed/36910630 http://dx.doi.org/10.3389/fonc.2023.999810 |
work_keys_str_mv | AT cervicatherine casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT sapizoltan casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT bedicsgabor casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT zajtaerik casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT hegyilajos casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT papayjudit casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT dezsokatalin casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT vargaedit casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT mudrakatalin casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT bodorcsaba casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene AT csokamonika casereportcompleteanddurableresponsetolarotrectinibtrkinhibitorinaninfantdiagnosedwithangiosarcomaharbouringakhdrbs1ntrk3fusiongene |